

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant ID3969

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Adienne Pharma & Biotech (melphalan) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Caribbean Leukaemia Trust • Anthony Nolan • Aplastic Anaemia Trust • Black Health Agency for Equality • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer52 • Children with Cancer UK • Chronic Lymphocytic Leukaemia Support Association • Chronic Myeloid Leukaemia Support Group • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Action • Macmillan Cancer Support • Maggie's Centres • Marie Curie • MDS UK Patient Support Group • MPN Voice • Myeloma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus Cancer Care • The UK Thalassaemia Society • WMUK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (busulfan and fludarabine) • Advanz Pharma (thiotepa) • Aspen (busulfan) • Baxter (cyclophosphamide) • Intraparm Laboratories (thiotepa) • Medac GmbH (treosulfan) • Pierre Fabre (busulfan) • Sandoz (cyclophosphamide) • Sanofi (fludarabine) • Tillomed Laboratories (busulfan and treosulfan) <p><u>Relevant research groups</u></p>

Provisional stakeholder list for the evaluation of melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant ID3969.

Issue date: March 2022

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Anaesthetists • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Psychosocial Oncology Society • British Society for Haematology • British Society of Blood and Marrow Transplantation • British Transplantation Society • Cancer Research UK • Children's Cancer and Leukaemia Group • NHS Blood and Transplant • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK Chronic Lymphocytic Leukaemia Forum • UK Clinical Pharmacy Association • United Kingdom Cutaneous Lymphoma Group • UK Myeloma Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS East and North Hertfordshire CCG • NHS England • NHS Milton Keynes CCG • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Haematological Malignancies Group • Cochrane UK • Genomics England • Institute of Cancer Research • Leukaemia UK • Leukaemia Busters • Lymphoma Research Trust • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.